ARMP · XBRL financial data

Armata Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ARMP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
General and administrative	7,966	8,281	7,437	11,649	13,184	12,409
Total operating expenses	22,410	28,296	42,454	45,419	47,610	41,538
Operating income (loss)	(21,587)	(23,822)	(36,946)	(40,890)	(42,436)	(36,634)
Interest income	28	5	29	179	—	—
Interest expense	628	64	0	2,626	—	—
Other income (expense)	(594)	667	29	(28,155)	23,520	(137,165)
Net income (loss)	(22,181)	(23,155)	(36,917)	(69,045)	(18,916)	(173,799)
Earnings per share, basic USD per share	(1.35)	(0.96)	(1.08)	(1.91)	(0.52)	(4.80)
Earnings per share, diluted USD per share	(1.35)	(0.96)	(1.08)	(1.91)	(0.89)	(4.80)
Weighted average shares, basic thousands of shares	16,415	24,104	34,294	36,076	36,161	36,239
Weighted average shares, diluted thousands of shares	16,415	24,104	34,294	36,076	59,060	36,239

Fiscal years (ARMP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	9,649	10,288	14,852	13,523	9,291	8,688
Prepaid and other current assets	636	1,718	10,259	2,265	1,273	1,508
Total current assets	10,846	14,995	27,047	19,151	11,308	10,668
Property and equipment, net	2,047	2,220	3,617	12,559	13,241	12,194
Right-of-use asset	10,790	35,852	43,035	44,717	41,687	33,911
Goodwill	3,490	3,490	3,490	3,490	3,490	3,490
Total assets	39,516	69,768	95,834	98,363	86,437	76,882
Accounts payable	956	1,138	1,678	1,585	766	921
Total current liabilities	6,705	4,814	24,873	16,461	48,249	8,947
Lease liability, non-current	10,877	36,480	31,804	28,583	27,694	26,533
Total liabilities	20,659	44,371	59,754	130,428	134,456	295,478
Accumulated deficit	(179,702)	(202,857)	(239,774)	(308,819)	(327,735)	(501,534)
Total stockholders' equity	18,857	25,397	36,080	(32,065)	(48,019)	(218,596)
Total liabilities and equity	39,516	69,768	95,834	98,363	86,437	76,882
Common shares outstanding (cover page) thousands of shares	24,940	30,727	36,145	36,149	36,183	36,633

Fiscal years (ARMP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(22,181)	(23,155)	(36,917)	(69,045)	(18,916)	(173,799)
Stock-based compensation	3,475	2,882	3,105	938	2,893	2,610
Depreciation and amortization	—	—	892	972	1,325	—
Net cash from operating activities	(18,270)	(23,575)	(32,481)	(47,423)	(37,551)	(25,763)
Purchases of property and equipment	824	1,304	2,211	8,144	1,879	542
Net cash from investing activities	(824)	(1,304)	(2,211)	(8,134)	(1,879)	(542)
Proceeds from issuing common stock	22,893	26,319	44,391	—	—	—
Net cash from financing activities	23,210	25,518	44,016	53,988	34,958	25,612
Net change in cash	4,116	639	9,324	(1,569)	(4,472)	(693)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Armata Pharmaceuticals	23,952	not reported	(8,666)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Imunon	6,864	not reported	(3,025)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Fibrogen	50,644	(1,474)	(3,991)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1,714	31*	(1,841)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Dare Bioscience	12,618	188	(6,775)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1,020	not reported	(5,841)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
Ovid Therapeutics	11,327	733	(17,594)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
vTv Therapeutics	86,643	0	(11,443)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Marimed	8,437	41,925	2,219*	403.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.